A5022167252- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Estrogen and related hormone effects
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Pharmacogenetics and Drug Metabolism
- Neutropenia and Cancer Infections
- Prostate Cancer Treatment and Research
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Fibroblast Growth Factor Research
- Breast Cancer Treatment Studies
- Cancer therapeutics and mechanisms
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Lung Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Cancer, Lipids, and Metabolism
- Lymphoma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Acute Lymphoblastic Leukemia research
University of St. Gallen
2016-2025
Kantonsspital St. Gallen
2015-2025
University of Basel
2023-2024
Palmetto Hematology Oncology
2024
Advanced Neural Dynamics (United States)
2022
University of Potsdam
2017-2020
Freie Universität Berlin
2017-2020
Roche (Switzerland)
2020
The Netherlands Cancer Institute
2004-2019
Hospital Base
2012-2019
For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% the SAKK 16/00 trial is an accepted standard care. We investigated additional benefit perioperative treatment durvalumab.Neoadjuvant consisted three cycles 100 mg/m2 85 once every 3 weeks two doses durvalumab 750 mg 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end...
Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce effective anti-tumor responses, they may also drive serious immune-related adverse events (irAEs). Identifying biomarkers to predict which patients will suffer from irAEs would enable more accurate clinical risk-benefit analysis ICI shed light on common or distinct mechanisms underpinning success irAEs.In this prospective multi-center...
Purpose Circulating cell-free DNA is present in increased amounts the blood of cancer patients, but clinical relevance this phenomenon remains unclear. We conducted a study to assess value circulating as prognostic marker patients with non–small-cell lung (NSCLC). Patients and Methods A standard protocol for quantification by real-time polymerase chain reaction was set up validated at two oncology units. One hundred eighty-five informed NSCLC 46 healthy controls were included study....
We performed a randomized phase II trial comparing pemetrexed with plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy.Main eligibility criteria were histologic or cytologic proof of advanced non-small-cell lung cancer (NSCLC), more than 3 months chemotherapy, normal organ function, and Eastern Cooperative Oncology Group performance status 0 to 2. Patients randomly assigned 500 mg/m(2) (arm A) area under the curve 5 B), both administered intravenously...
Antifolates are structural analogs of folates, essential one-carbon donors in the synthesis DNA mammalian cells. inhibitors key enzymes folate metabolism, namely dihydrofolate reductase, β-glycinamide ribonucleotide transformylase, 5'-amino-4'-imidazolecarboxamide and thymidylate synthetase. Methotrexate is one earliest anticancer drugs extensively used lymphoma, acute lymphoblastic leukemia, osteosarcoma, among others. Pemetrexed has been approved combination with cisplatin as first-line...
We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD) variants to predict severe early-onset fluoropyrimidine (FP) toxicity, in particular a recently discovered haplotype hapB3 and linked deep intronic splice site mutation c.1129-5923C>G. Selected regions DPYD were sequenced prospectively collected germline DNA 500 patients receiving FP-based chemotherapy. Associations haplotypes with hematologic, gastrointestinal, infectious, dermatologic toxicity therapy...
<h3>Importance</h3> Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein anticancer treatments. <h3>Objective</h3> To safety and activity fully human TNF IgG1 monoclonal antibody BMS-986156 with or without nivolumab patients advanced tumors. <h3>Design, Setting, Participants</h3> This global, open-label, phase 1/2a study enrolled 292 18 years...
Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) remain demand. Since anti-tumor activation is a process, early dynamic changes of the acute-phase reactant C reactive protein (CRP) may serve as predictive on-treatment biomarker. In retrospective (N=105) and prospective (N=108) ICB-treated NSCLC cohort, CRP kinetics were stratified after start immunotherapy until weeks 4, 6, 12 follows: an doubling...
•EMA recommendations regarding pre-treatment DPD testing have supported the widespread implementation of in Europe.•Key factors for successful are test reimbursement and existence clear clinical guidelines.•Knowledge about applicability pharmacogenetics among clinicians should be further improved. BackgroundThe main cause fluoropyrimidine-related toxicity is deficiency metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, European Medicines Agency (EMA) recommended two methods...
Abstract Background: The aim of this study was to quantitatively assess the effect anthropometric and biochemical variables third-space effusions on paclitaxel pharmacokinetics in solid tumor patients. Materials Methods: Plasma concentration-time data were collected patients with non–small cell lung cancer (n = 84), ovarian 40), various tumors 44), totaling 168 Paclitaxel given as a 3-hour infusion 163) at doses ranging from 100 250 mg/m2, or 24-hour 5) dose 135 175 mg/m2. Data analyzed...
Abstract Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time above plasma concentration of 0.05 0.2 μmol/L (tC &gt; 0.05−0.2) predicts neutropenia. The objective this study was build a population pharmacokinetic-pharmacodynamic model paclitaxel/carboplatin patients. Experimental Design: One hundred thirty-nine patients...
Abstract: Antifolates are structural analogs of folates, essential one-carbon donors in the synthesis DNA mammalian cells. inhibitors key enzymes folate metabolism, namely dihydrofolate reductase, β-glycinamide ribonucleotide transformylase, 5'-amino-4'-imidazolecarboxamide and thymidylate synthetase. Methotrexate is one earliest anticancer drugs extensively used lymphoma, acute lymphoblastic leukemia, osteosarcoma, among others. Pemetrexed has been approved combination with cisplatin as...
There is ongoing debate about nonpalliative primary tumor surgery in metastatic breast cancer patients. This issue has become even more relevant with the introduction of increasingly sensitive imaging modalities.Metastatic patients were identified SEER registry between 1998 and 2009. The effect on overall cancer-specific mortality using risk-adjusted Cox proportional hazard regression modeling stratified propensity score matching was assessed.Overall, 16,247 women included. Of those 7600...
<h3>Background</h3> Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), potential exposure-response relationship has recently been reported and may argue against the current strategies. The primary objectives were to determine nivolumab pharmacokinetics (PK) assess between drug clearance clinical outcome NSCLC, melanoma, renal (RCC). <h3>Methods</h3> In this prospective observational cohort study, individual...
<h3>Background</h3> Long-term survival of stage IV melanoma patients has improved significantly with the development immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. <h3>Methods</h3> We investigated role melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific before treatment, after one week six nine weeks treatment. Cohort 2 consisted...